JP2005504550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504550A5 JP2005504550A5 JP2003534582A JP2003534582A JP2005504550A5 JP 2005504550 A5 JP2005504550 A5 JP 2005504550A5 JP 2003534582 A JP2003534582 A JP 2003534582A JP 2003534582 A JP2003534582 A JP 2003534582A JP 2005504550 A5 JP2005504550 A5 JP 2005504550A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cell cycle
- reporter
- construct
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 322
- 230000022131 cell cycle Effects 0.000 claims description 161
- 238000000034 method Methods 0.000 claims description 68
- 230000018486 cell cycle phase Effects 0.000 claims description 60
- 150000007523 nucleic acids Chemical class 0.000 claims description 52
- 108010060385 Cyclin B1 Proteins 0.000 claims description 49
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims description 49
- 239000000126 substance Substances 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 43
- 238000012360 testing method Methods 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000005090 green fluorescent protein Substances 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 35
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 238000006731 degradation reaction Methods 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 230000004807 localization Effects 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 18
- 210000004962 mammalian cell Anatomy 0.000 claims description 16
- 238000012544 monitoring process Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 206010059866 Drug resistance Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 238000013519 translation Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 6
- 108091006047 fluorescent proteins Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 108010068192 Cyclin A Proteins 0.000 claims description 4
- 108090000257 Cyclin E Proteins 0.000 claims description 4
- 102000003909 Cyclin E Human genes 0.000 claims description 4
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 108010060273 Cyclin A2 Proteins 0.000 claims description 3
- 108091005971 Wild-type GFP Proteins 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 238000000354 decomposition reaction Methods 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 101150012716 CDK1 gene Proteins 0.000 claims description 2
- 102100037912 Cyclin-dependent kinase 11A Human genes 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 101000738403 Homo sapiens Cyclin-dependent kinase 11A Proteins 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 102000004459 Nitroreductase Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 2
- 108020001162 nitroreductase Proteins 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 claims 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 18
- 230000011278 mitosis Effects 0.000 description 11
- 230000018199 S phase Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000010337 G2 phase Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 8
- 102000016736 Cyclin Human genes 0.000 description 8
- 108700008625 Reporter Genes Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000006369 cell cycle progression Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 7
- WZNJWVWKTVETCG-YFKPBYRVSA-N L-mimosine Chemical compound OC(=O)[C@@H](N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-YFKPBYRVSA-N 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 229950002289 mimosine Drugs 0.000 description 7
- 230000000394 mitotic effect Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 230000010190 G1 phase Effects 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 230000032823 cell division Effects 0.000 description 5
- 230000033077 cellular process Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 102000002554 Cyclin A Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000024355 spindle assembly checkpoint Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- -1 Amino Chemical group 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229930189662 Corticin Natural products 0.000 description 1
- 241001643392 Cyclea Species 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 description 1
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical class NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0123856.7A GB0123856D0 (en) | 2001-10-05 | 2001-10-05 | Method for determining cell cycle position |
| PCT/GB2002/004258 WO2003031612A2 (en) | 2001-10-05 | 2002-09-12 | Method for determining cell cycle position |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005504550A JP2005504550A (ja) | 2005-02-17 |
| JP2005504550A5 true JP2005504550A5 (enExample) | 2008-09-04 |
| JP4607454B2 JP4607454B2 (ja) | 2011-01-05 |
Family
ID=9923245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534582A Expired - Fee Related JP4607454B2 (ja) | 2001-10-05 | 2002-09-12 | 細胞周期位置を決定する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7235401B2 (enExample) |
| EP (1) | EP1432819B1 (enExample) |
| JP (1) | JP4607454B2 (enExample) |
| AT (1) | ATE368753T1 (enExample) |
| AU (1) | AU2002326036B2 (enExample) |
| CA (1) | CA2461133C (enExample) |
| DE (1) | DE60221550T2 (enExample) |
| ES (1) | ES2290326T3 (enExample) |
| GB (1) | GB0123856D0 (enExample) |
| IL (1) | IL160908A0 (enExample) |
| WO (1) | WO2003031612A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2401431B (en) * | 2003-04-02 | 2005-04-27 | Amersham Biosciences Uk Ltd | Method of, and computer software for, classification of cells into subpopulations |
| GB0307684D0 (en) * | 2003-04-02 | 2003-05-07 | Amersham Biosciences Uk Ltd | Determining cell cycle phase data |
| EP1624748A4 (en) * | 2003-05-08 | 2009-01-07 | Health Research Inc | TRANSGENIC ANIMAL MODEL FOR STEM OR TRANSGENIC CELLS |
| US7745123B2 (en) | 2004-07-23 | 2010-06-29 | Ge Healthcare Uk Limited | Cell cycle reporting cell line |
| CN101052646B (zh) * | 2004-07-23 | 2015-10-21 | 通用电气医疗集团英国有限公司 | 细胞周期阶段标志物 |
| JP5143552B2 (ja) | 2004-07-23 | 2013-02-13 | ジーイー・ヘルスケア・ユーケイ・リミテッド | 細胞周期フェーズマーカー |
| JP5408839B2 (ja) * | 2006-10-20 | 2014-02-05 | オリンパス株式会社 | 細胞周期解析方法 |
| EP2275567A1 (en) * | 2009-07-15 | 2011-01-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nucleic acid expression construct and its use as a cell proliferation marker |
| US10100305B2 (en) | 2011-07-15 | 2018-10-16 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288641A (en) * | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| FR2658204A1 (fr) * | 1990-02-12 | 1991-08-16 | Inst Nat Sante Rech Med | Nouvelles compositions de cycline a humaine, sequence nucleotidique correspondante, et agents de detection ou de diagnostic de mutations hepatocellulaires induites par le virus hbv. |
| US6159691A (en) * | 1996-05-15 | 2000-12-12 | Prolifix Limited | Assay for a putative regulator of cell cycle progression |
| US6124128A (en) * | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
| US6048693A (en) * | 1996-10-16 | 2000-04-11 | Bittech, Inc. | Phenotypic assays of cyclin/cyclin-dependent kinase function |
| US6461813B2 (en) * | 1998-09-21 | 2002-10-08 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in cell cycle regulation |
| DE19831420A1 (de) * | 1998-07-14 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren |
| US6764852B2 (en) * | 1999-01-26 | 2004-07-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Internal ribosome entry site, vector containing same and uses thereof |
| GB0002261D0 (en) * | 2000-02-02 | 2000-03-22 | Amersham Pharm Biotech Uk Ltd | Fluorescent detection method & reagent |
-
2001
- 2001-10-05 GB GBGB0123856.7A patent/GB0123856D0/en not_active Ceased
-
2002
- 2002-09-12 AU AU2002326036A patent/AU2002326036B2/en not_active Ceased
- 2002-09-12 ES ES02760417T patent/ES2290326T3/es not_active Expired - Lifetime
- 2002-09-12 EP EP02760417A patent/EP1432819B1/en not_active Expired - Lifetime
- 2002-09-12 DE DE60221550T patent/DE60221550T2/de not_active Expired - Lifetime
- 2002-09-12 AT AT02760417T patent/ATE368753T1/de not_active IP Right Cessation
- 2002-09-12 WO PCT/GB2002/004258 patent/WO2003031612A2/en not_active Ceased
- 2002-09-12 JP JP2003534582A patent/JP4607454B2/ja not_active Expired - Fee Related
- 2002-09-12 US US10/491,762 patent/US7235401B2/en not_active Expired - Fee Related
- 2002-09-12 IL IL16090802A patent/IL160908A0/xx unknown
- 2002-09-12 CA CA002461133A patent/CA2461133C/en not_active Expired - Fee Related
-
2007
- 2007-06-12 US US11/761,441 patent/US20070238123A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070238123A1 (en) | Method for determining cell cycle position | |
| AU751163B2 (en) | Rapidly degrading GFP-fusion proteins and methods of use | |
| JP2011015685A (ja) | 新規な発現ベクター | |
| EP2138577B1 (en) | Probe for visualizing cell cycle | |
| US6093808A (en) | IκBEGFP constructs, cell lines and methods of use | |
| JP2005504550A5 (enExample) | ||
| Hauser et al. | Expression of the green fluorescent protein in Paramecium tetraurelia | |
| AU2005263993B2 (en) | Cell cycle reporting cell line | |
| KR102074590B1 (ko) | 자가포식체 탐침용 프로브 및 이를 이용한 탐침 방법 | |
| Brini et al. | Targeting of aequorin for calcium monitoring in intracellular compartments | |
| US7745123B2 (en) | Cell cycle reporting cell line | |
| EP1674478A1 (en) | Fusion proteins and method for determining protein-protein-interactions in living cells and cell lysates, nucleic acids encoding these fusion proteins, as well as vectors and kits containing these | |
| JP2023121261A (ja) | インプラント材料を評価するための改変骨芽細胞様細胞 | |
| CN108486113A (zh) | 实现两个基因等量表达的基于2a裂解肽的多基因元件及表达载体和应用 | |
| Petrovskaya et al. | An analysis of the effect of the internal ribosome entry site of the encephalomyocarditis virus on the expression of the second gene in the bicistronic matrix in neurons of primary hippocampal cultures | |
| KR100791859B1 (ko) | ｐ53 종양 억제단백질과 형광단백질의 융합단백질을발현하는 형질전환 세포주 및 이를 이용한 ｐ53 종양억제단백질의 활성과 관련된 물질의 검색방법 | |
| AU2024227900A1 (en) | R-loop sensor | |
| Benassayag et al. | Point mutations within and outside the homeodomain identify sequences required for proboscipedia homeotic function in Drosophila | |
| JP2003199581A (ja) | マーカー遺伝子を用いた生体機能分子の評価並びに同定方法 | |
| CN108486114A (zh) | 实现两个基因等量表达的基因元件及表达载体 | |
| CN108588122A (zh) | 基于2a裂解肽实现两个基因等量表达的多基因元件及表达载体和应用 |